Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I XAGE1 long-peptide vaccine in advanced lung adenocarcinoma
jRCTs061180010Phase 1Completed
- Sponsor
- Pole Star Therapeutics
- Start
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of XAGE1B long-peptide vaccine in Non-small cell lung cancer adenocarcinoma (NSCLC) (3 cohorts), sponsored by Pole Star Therapeutics. Primary endpoint: Safety. Started Jun 2017; status: completed.
02
Drugs
XAGE1B long-peptide vaccine
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCTs061180010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180010.